GlassScriptPhysician profile
Douglas N Delorenzo
NPI 1093898975
$1,969.34
in general payments reported to CMS, 2019-2025
26 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $147 · 2021: $122 · 2022: $432 · 2023: $404 · 2024: $293 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $325.54 | 2022-2025 | Nuzyra |
| Zimmer Biomet Holdings, INC. | $238.00 | 2020-2022 | |
| Integra Lifesciences Corporation | $216.51 | 2019-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $169.13 | 2019-2024 | Jublia |
| Smith+Nephew, INC. | $168.59 | 2020-2023 | Collagenase Santyl, Regranex |
| Organogenesis INC. | $115.28 | 2019-2022 | |
| Melinta Therapeutics, LLC | $99.16 | 2019 | |
| Sebela Pharmaceuticals INC. | $89.80 | 2019-2023 | Naftin |
| Horizon Therapeutics Plc | $82.47 | 2019 | |
| Stryker Corporation | $59.25 | 2023-2024 | Easyfuse, Sonicanchor, Augment Injectable |
| Convatec INC. | $47.45 | 2023-2024 | |
| Vertex Pharmaceuticals Incorporated | $44.04 | 2024-2025 | |
| Dynasplint Systems INC. | $43.76 | 2019-2025 | Dynasplint |
| Paragon 28, INC. | $38.18 | 2020-2021 | |
| Abbvie INC. | $32.28 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Next Science LLC | $24.45 | 2023 | Xperience, Surgx, Blastx |
| Abbott Laboratories | $23.07 | 2019 | |
| Kerecis Limited | $21.73 | 2020 | |
| Boston Scientific Corporation | $20.35 | 2019 | |
| Royal Biologics, INC. | $18.74 | 2020 | |
| Medtronic, INC. | $18.43 | 2024 | Intellis Adaptivestim |
| Amgen INC. | $17.13 | 2025 | Krystexxa |
| Djo, LLC | $16.63 | 2019 | |
| Merck Sharp & Dohme LLC | $14.17 | 2019 | |
| Ibsa Pharma INC. | $13.07 | 2023 | Tirosint, Licart |
| Wright Medical Technology, INC. | $12.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Delorenzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.